Search for Clinical Trial Results

Sponsored By

Diabetes Insipidus - 29 Studies Found

Status Study
Completed Study Name: Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion
Condition:
  • Inappropriate ADH Syndrome
  • Hyponatremia

Date: 2005-12-12
Interventions: Drug: SR121463B
Completed Study Name: Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion
Condition:
  • Syndrome of Inappropriate ADH (SIADH) Secretion
  • Hyponatremia

Date: 2002-03-29
Interventions: Drug: satavaptan (SR121463B)
Completed Study Name: V2 Receptor Effects on Fluid Regulation and Performance
Condition:
  • Electrolyte Imbalance
  • Hyponatremia
  • Hypernatremia
    • Date: 2014-03-10
    Interventions: Drug: V2R (Vasopressin 2 receptor) All ten subjects were used as their own controls in this double-blind
Completed Study Name: Safety Profiles of Liver Biopsy in Hemodialysis Patients With Chronic Viral Hepatitis Pre-treated With Vasopressin
Condition:
  • Chronic Hepatitis C
  • Chronic Hepatitis B
  • Biopsy
  • Date: 2008-03-05
    Interventions: Procedure: Percutaneous liver biopsy Two passes of PLB from the right hepatic lobe by US guidance (Toshi
Completed Study Name: Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia (The GOLD-Study)
Condition: Primary Polydipsia
Date: 2016-03-30
Interventions:
  • Drug: Dulaglutide Treatment wi
Completed Study Name: Copeptin in Differentiation of Polyuria and Polydipsia
Condition:
  • Polyuria
  • Polydipsia

Date: 2010-01-25
Completed Study Name: Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT).
Condition: Chronic Heart Failure
Date: 2002-03-29
Interventions: Drug: Vasopressin V2 Receptor Antagonist
Completed Study Name: DILIPO (DILutIonal HyPOnatremia)
Condition: Congestive Heart Failure
Date: 2006-01-09
Interventions: Drug: SR121463B
NOT_YET_RECRUITING Study Name: Effects of Intranasal Oxytocin in Patients With Central Diabetes Insipidus
Condition: Central Diabetes Insipidus
Date: 2025-08-02
Interventions: 4 IU intranasal oxytocin, 24 IU intranasal oxytocin or placebo
<<< Previous